Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 18;28(4):1959.
doi: 10.3390/molecules28041959.

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Lozan Todorov  1 , Irena Kostova  1
Affiliations
Review

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Lozan Todorov et al. Molecules. .

Abstract

Since the accidental discovery of the anticancer properties of cisplatin more than half a century ago, significant efforts by the broad scientific community have been and are currently being invested into the search for metal complexes with antitumor activity. Coordination compounds of transition metals such as platinum (Pt), ruthenium (Ru) and gold (Au) have proven their effectiveness as diagnostic and/or antiproliferative agents. In recent years, experimental work on the potential applications of elements including lanthanum (La) and the post-transition metal gallium (Ga) in the field of oncology has been gaining traction. The authors of the present review article aim to help the reader "catch up" with some of the latest developments in the vast subject of coordination compounds in oncology. Herewith is offered a review of the published scientific literature on anticancer coordination compounds of Pt, Ru, Au, Ga and La that has been released over the past three years with the hope readers find the following article informative and helpful.

Keywords: cancer research; coordination complexes; gallium; gold; lanthanum; oncology; platinum; ruthenium.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Modified pyriplatin, described in [22].
Figure 2
Figure 2
The folate-Pt(II) complex described in [24].
Figure 3
Figure 3
Three Pt(II)-terpyridine complexes, described in [25].
Figure 4
Figure 4
The pyridine-based complexes 1 and 2 described in [27].
Figure 5
Figure 5
The most potent antiproliferative complex described in [28].
Figure 6
Figure 6
The complexes described in [30].
Figure 7
Figure 7
The complexes described in [32].
Figure 8
Figure 8
The complexes described in [33].
Figure 9
Figure 9
The macrocyclic Pt(II) complexes described in [36].
Figure 10
Figure 10
The diazido-complex described in [42].
Figure 11
Figure 11
The complexes described by [50].
Figure 12
Figure 12
The complex described by [53].
Figure 13
Figure 13
The complexes presented in [58].
Figure 14
Figure 14
Complexes 1 and 2 presented in [60].
Figure 15
Figure 15
The complexes presented in [61].
Figure 16
Figure 16
The most active complex presented in [62].
Figure 17
Figure 17
The complexes presented in [64].
Figure 18
Figure 18
The complexes presented in [71].
Figure 19
Figure 19
One of the complexes presented in [9].
Figure 20
Figure 20
One of the complexes presented in [91].
Figure 21
Figure 21
The ligands presented in [92].
Figure 22
Figure 22
The complexes presented in [84].
Figure 23
Figure 23
The complexes presented in [93].
Figure 24
Figure 24
Structures of KP46 (a) and its analogues (b) presented in [94,95].
Figure 25
Figure 25
The complexes presented in [102].
Figure 26
Figure 26
The complexes presented in [104].
Figure 27
Figure 27
The complexes presented in [105].
Figure 28
Figure 28
The complexes presented in [110].
Figure 29
Figure 29
One of the complexes presented in [112].
Figure 30
Figure 30
One of the complexes presented in [113].
Figure 31
Figure 31
One of the complexes presented in [114].
Figure 32
Figure 32
Some of the complexes presented in [115].
Figure 33
Figure 33
One of the complexes presented in [117].
Figure 34
Figure 34
One of the complexes presented in [119].
Figure 35
Figure 35
The ligand of the complex presented in [127].
Figure 36
Figure 36
The ligands of the complexes presented in [130].
Figure 37
Figure 37
The ligands of the complexes presented in [132].
See this image and copyright information in PMC

References

    1. Arruebo M., Vilaboa N., Sáez-Gutierrez B., Lambea J., Tres A., Valladares M., González-Fernández Á. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3:3279–3330. doi: 10.3390/cancers3033279. - DOI - PMC - PubMed
    1. Pham T.C., Nguyen V.-N., Choi Y., Lee S., Yoon J. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem. Rev. 2021;121:13454–13619. doi: 10.1021/acs.chemrev.1c00381. - DOI - PubMed
    1. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D. Photodynamic therapy of cancer: An update. CA Cancer J. Clin. 2011;61:250–281. doi: 10.3322/caac.20114. - DOI - PMC - PubMed
    1. Hausinger R.P. New metal cofactors and recent metallocofactor insights. Curr. Opin. Struct. Biol. 2019;59:1–8. doi: 10.1016/j.sbi.2018.12.008. - DOI - PubMed
    1. Grass G., Rensing L., Rensing C. Metal toxicity. Metallomics. 2011;3:1095–1097. doi: 10.1039/c1mt90048j. - DOI - PubMed

LinkOut - more resources